Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)

Status: Completed
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to determine the safety and efficacy of post-transplant cyclophosphamide and a post-transplant infusion of donor cells, that have been specially processed to remove alpha beta t-cells, in patients undergoing a haploidentical allogeneic stem cell transplant to help reduce the risk of relapse without increasing the risk of graft-versus-host disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 65
Healthy Volunteers: f
View:

• Neoplastic hematological disorder with indication of allogeneic transplant

• No available suitable HLA-matched donor

• Adequate cardiac, pulmonary, renal, and hepatic function

• Karnofsky performance status score greater than or equal to 70%

Locations
United States
Alabama
UAB Medical Center (University of Alabama at Birmingham)
Birmingham
Time Frame
Start Date: 2014-10-09
Completion Date: 2018-03-13
Participants
Target number of participants: 7
Treatments
Other: Alpha-beta depleted T-cell infusion
Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
Sponsors
Leads: Ayman Saad

This content was sourced from clinicaltrials.gov

Similar Clinical Trials